Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington's Disease and Tardive Dyskinesia.

Publication Year: 2023

DOI:
10.2147/TCRM.S279332

PMCID:
PMC10697845

PMID:
38074485

Journal Information

Full Title: Ther Clin Risk Manag

Abbreviation: Ther Clin Risk Manag

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Health Care Sciences & Services

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure SF received salary support as the medical monitor for the TETRA-HD trial and principal investigator for the FIRST-HD and ARC-HD trials. He has served as a consultant to Teva Pharmaceuticals. AA reports no conflicts of interest in this work."

Evidence found in paper:

"Disclosure: SF received salary support as the medical monitor for the TETRA-HD trial and principal investigator for the FIRST-HD and ARC-HD trials. He has served as a consultant to Teva Pharmaceuticals. AA reports no conflicts of interest in this work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025